Wall Street
Price Targets

2MT Price Targets Summary
Athenex Inc

There are no price targets for 2MT.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Athenex Inc Competitors:
Price Targets
KMDA
Kamada Ltd
87% Upside
EDT
Spectral Medical Inc
149% Upside
SPRY
ARS Pharmaceuticals Inc
145% Upside
005690
Pharmicell Co Ltd
13% Upside
688428
InnoCare Pharma Ltd
81% Upside
688278
Xiamen Amoytop Biotech Co Ltd
20% Upside
OCC
Orthocell Ltd
23% Upside
RNA
Avidity Biosciences Inc
3% Upside

Revenue
Forecast

Revenue Estimate
Athenex Inc

For the last 7 years the compound annual growth rate for Athenex Inc's revenue is 33%. The projected CAGR for the next 2 years is 2%.

33%
Past Growth
2%
Estimated Growth
Estimates Accuracy
-6%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Athenex Inc

Operating Income forecast
is not available for
Athenex Inc

Net Income
Forecast

Net Income Estimate
Athenex Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is 2MT's stock price target?
Not Available

2MT doesn't have any price targets made by Wall Street professionals.

What is Athenex Inc's Revenue forecast?
Projected CAGR
2%

For the last 7 years the compound annual growth rate for Athenex Inc's revenue is 33%. The projected CAGR for the next 2 years is 2%.

Back to Top